Zobrazeno 1 - 10
of 13
pro vyhledávání: ''
Autor:
Yashaswi Shrestha, Ronald Herbst, Rajiv Raja, Maria Libera Ascierto, Michael Oberst, Philip Martin, Melissa de los Reyes, Nabendu Pore, Raymond Rothstein, John Meekin, Ashok K. Gupta, Melanie M. Frigault, Stephen Blackmore, Ina Bisha, Nathan Standifer, Shaad Essa Abdullah, Theresa Proia, Matthew Griffin, Phillip A. Dennis, Rebecca A. Halpin, Song Wu, Ricardo J Miragaia, Kathy Mulgrew, J. Carl Barrett, Maria Jure-Kunkel
Publikováno v:
Cancer Discovery. 11:2828-2845
Mutations in the STK11 (LKB1) gene regulate resistance to PD-1/PD-L1 blockade. This study evaluated this association in patients with nonsquamous non–small cell lung cancer (NSCLC) enrolled in three phase I/II trials. STK11 mutations were associate
Autor:
Kei-ichiro Arimoto, Leo J.Y. Kim, Balázs Győrffy, Klaus-Peter Knobeloch, Dong-Er Zhang, Hua Cheng, Christoph Burkart, Xiang-Dong Fu, Jeremy N. Rich, Hu Cang, Jun-Bao Fan, Yu Zhou, Hui-Zhong Xu, Ming Yan, Sayuri Miyauchi, Dan Liu
Publikováno v:
Cancer Discov
Type I interferons (IFN), which activate many IFN-stimulated genes (ISG), are known to regulate tumorigenesis. However, little is known regarding how various ISGs coordinate with one another in developing antitumor effects. Here, we report that the I
Autor:
Christine A. Pratilas, Sharmeen Uddin, Amy Allen, Zhan Yao, Jiawan Wang, Ira J. Dunkel, Barry S. Taylor, Neal Rosen, Philip Jonsson, Alice Can Ran Qin, Katia Manova, Sofia Haque, David J. Pisapia, Mary Petriccione, Marc K. Rosenblum
Publikováno v:
Cancer Discovery. 8:1130-1141
BRAFV600E hyperactivates ERK and signals as a RAF inhibitor–sensitive monomer. Although RAF inhibitors can produce impressive clinical responses in patients with mutant BRAF tumors, the mechanisms of resistance to these drugs are incompletely chara
Autor:
Jonathan H. Sheehan, Carlos L. Arteaga, Michael F. Berger, James P. Koch, Richard E. Cutler, Vincent A. Miller, Ariella B. Hanker, Rebecca J. Nagy, Gregory Sliwoski, David M. Hyman, Christine M. Lovly, Jie He, Alshad S. Lalani, Jens Meiler, Monica Red Brewer, David B. Solit, Richard B. Lanman, Darren Cross
Publikováno v:
Cancer Discovery. 7:575-585
We report a HER2T798I gatekeeper mutation in a patient with HER2L869R-mutant breast cancer with acquired resistance to neratinib. Laboratory studies suggested that HER2L869R is a neratinib-sensitive, gain-of-function mutation that upon dimerization w
Autor:
Christopher J. Morrow, Zhiqiang Li, Joanne Wilson, Sarat Chandarlapaty, Kathryn E. Carlson, Pedram Razavi, Teresa S. Martin, José Baselga, Anne U. Goeppert, Mandy Lawson, Wai Lin Wong, Elisa de Stanchina, Anne Marie Mazzola, Geoffrey L. Greene, John A. Katzenellenbogen, Hazel M. Weir, Aaron Smith, Weiyi Toy, Sharmeen Uddin, Sean W. Fanning
Publikováno v:
Cancer Discovery. 7:277-287
Recent studies have identified somatic ESR1 mutations in patients with metastatic breast cancer and found some of them to promote estrogen-independent activation of the receptor. The degree to which all recurrent mutants can drive estrogen-independen
Autor:
Aram F. Hezel, Nabeel Bardeesy, Cyril H. Benes, Jia-Chi Yeo, James T. Webber, Kevan M. Shokat, Travis Sullivan, Benjamin P. Kleinstiver, Roger L. Jenkins, Ultan McDermott, Yusuke Mizukami, Leah J. Damon, Regina K. Egan, Lei Shi, Supriya K. Saha, J. Keith Joung, John D. Gordan, Patricia Greninger, Rebecca S. Levin, Andrew S. Liss, Yasutaka Kato, Andrew X. Zhu, Kimberly M. Rieger-Christ, Mortada S. Najem, Lipika Goyal, Cristina R. Ferrone, Phuong Vu, Mathew J. Garnett
Publikováno v:
Cancer discovery, vol 6, iss 7
Intrahepatic cholangiocarcinoma (ICC) is an aggressive liver bile duct malignancy exhibiting frequent isocitrate dehydrogenase (IDH1/IDH2) mutations. Through a high-throughput drug screen of a large panel of cancer cell lines, including 17 biliary tr
Autor:
Ilaria Conti, Sheng-Bin Peng, James J. Starling, Igor Mochalkin, Henry James Robert, Sean Buchanan, Robert D. Van Horn, Lysiane Huber, Gregory D. Plowman, Swee Seong Wong, Youyan Zhang, Vipin Yadav, Yong Gang Yue, Shih-Hsun Chen, Tinggui Yin
Publikováno v:
Cancer Discovery. 6:300-315
We have identified previously undiscovered BRAF in-frame deletions near the αC-helix region of the kinase domain in pancreatic, lung, ovarian, and thyroid cancers. These deletions are mutually exclusive with KRAS mutations and occur in 4.21% of KRAS
Autor:
Russo, Mariangela, Siravegna, Giulia, Blaszkowsky, Lawrence S., Corti, Giorgio, Crisafulli, Giovanni, Ahronian, Leanne G., Mussolin, Benedetta, Kwak, Eunice L., Buscarino, Michela, Lazzari, Luca, Valtorta, Emanuele, Truini, Mauro, Jessop, Nicholas A., Robinson, Hayley E., Hong, Theodore S., Mino Kenudson, Mari, DI NICOLANTONIO, Federica, Thabet, Ashraf, Sartore Bianchi, Andrea, Siena, Salvatore, Iafrate, John, Bardelli, Alberto, Corcoran, Ryan B., joint co last authorshipjoint corresponding authorship
Publikováno v:
Cancer Discovery. 6:147-153
How genomic heterogeneity associated with acquired resistance to targeted agents affects response to subsequent therapy is unknown. We studied EGFR blockade in colorectal cancer to assess whether tissue and liquid biopsies can be integrated with radi
Autor:
Jens Meiler, Jonathan H. Sheehan, Timothy M. Shaver, Jean-Nicolas Gallant, Sally York, Mark G. Kris, Jennifer A. Pietenpol, Marc Ladanyi, Siraj M. Ali, Christine M. Lovly, Monica Red Brewer, Vincent A. Miller, Doron Lipson, Mark Bailey, Raghu Chandramohan
Publikováno v:
Cancer Discovery. 5:1155-1163
Oncogenic EGFR mutations are found in 10% to 35% of lung adenocarcinomas. Such mutations, which present most commonly as small in-frame deletions in exon 19 or point mutations in exon 21 (L858R), confer sensitivity to EGFR tyrosine kinase inhibitors
Autor:
Jaime L. Wolfe, Cynthia L. Sears, Shaoguang Wu, David L. Huso, Xinqun Wu, Drew M. Pardoll, Abby L. Geis, Hongni Fan, Franck Housseau
Publikováno v:
Cancer Discovery. 5:1098-1109
Many epithelial cancers are associated with chronic inflammation. However, the features of inflammation that are procarcinogenic are not fully understood. Regulatory T cells (Treg) typically restrain overt inflammatory responses and maintain intestin